- Home
- MOBX vs INAB Comparison
MOBX vs INAB Comparison
Compare MOBX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- INAB
- Stock Information
- Founded
- MOBX 2020
- INAB 2016
- Country
- MOBX United States
- INAB United States
- Employees
- MOBX N/A
- INAB N/A
- Industry
- MOBX
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- INAB Health Care
- Exchange
- MOBX Nasdaq
- INAB Nasdaq
- Market Cap
- MOBX 29.9M
- INAB 24.0M
- IPO Year
- MOBX N/A
- INAB 2021
- Fundamental
- Price
- MOBX $0.58
- INAB $0.32
- Analyst Decision
- MOBX
- INAB Strong Buy
- Analyst Count
- MOBX 0
- INAB 3
- Target Price
- MOBX N/A
- INAB $7.75
- AVG Volume (30 Days)
- MOBX 132.8K
- INAB 833.0K
- Earning Date
- MOBX 11-29-2024
- INAB 11-12-2024
- Dividend Yield
- MOBX N/A
- INAB N/A
- EPS Growth
- MOBX N/A
- INAB N/A
- EPS
- MOBX N/A
- INAB N/A
- Revenue
- MOBX $3,921,000.00
- INAB N/A
- Revenue This Year
- MOBX N/A
- INAB N/A
- Revenue Next Year
- MOBX N/A
- INAB N/A
- P/E Ratio
- MOBX N/A
- INAB N/A
- Revenue Growth
- MOBX 214.69
- INAB N/A
- 52 Week Low
- MOBX $0.55
- INAB $0.22
- 52 Week High
- MOBX $12.50
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- MOBX 31.47
- INAB 50.03
- Support Level
- MOBX $0.60
- INAB $0.31
- Resistance Level
- MOBX $0.68
- INAB $0.37
- Average True Range (ATR)
- MOBX 0.07
- INAB 0.05
- MACD
- MOBX -0.00
- INAB -0.00
- Stochastic Oscillator
- MOBX 0.00
- INAB 30.77
About MOBX Mobix Labs Inc.
Mobix Labs Inc is a fabless semiconductor company developing disruptive next generation wireless and connected solutions that are designed to cater to a broad range of applications in markets including 5G infrastructure, satellite communications, automotive, consumer electronics, e-mobility, healthcare, infrastructure and defense.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.